Journal of Cystic Fibrosis 2014

5 papers
The 2014 edition of the *Journal of Cystic Fibrosis* highlighted advancements in therapeutic monitoring and targeted treatment strategies. Research themes included the use of hyperpolarized helium-3 MRI to evaluate the effects of ivacaftor on lung ventilation in patients with the G551D-CFTR mutation. Clinical trials also investigated alternative delivery methods for existing treatments, such as the sinonasal inhalation of dornase alfa using vibrating aerosols, and documented specific approaches to eradicating *Pseudomonas aeruginosa* from the respiratory tract. Beyond clinical interventions, the journal published work on the three-dimensional structural modeling of the CFTR protein to aid in the development of pharmacological correctors. Metabolic research was also represented, with studies utilizing the disposition index to identify beta-cell dysfunction in patients who otherwise maintained normal glucose tolerance. Prolific contributors to the year's volume included Jochen G. Mainz, Deborah Froh, and John P. Mugler. These publications reflect a trend toward combining molecular insights with refined diagnostic techniques to address both the respiratory and systemic manifestations of cystic fibrosis.

Top Authors

AuthorPapers
Brice Hoffmann1

Papers

Title
300 Pseudomonas aeruginosa colonization in a CF child's upper and lower airways: a father's meticulous approach to successful eradication
Disposition index identifies defective beta-cell function in cystic fibrosis subjects with normal glucose tolerance
Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: A double-blind placebo-controlled cross-over trial
WS23.1 Models of the 3D structure of CFTR: from the understanding of the protein functions to the design of correctors
WS3.2 The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation